David Perlmutter
David Perlmutter is a neurologist and author focusing on cognitive health and neurodegenerative disorders. His published research investigates Alzheimer's disease prevention, intracerebral fructose and uric acid metabolism, and brain inflammation. His work also covers clinical evaluations of treatments for Parkinson's disease, gluten sensitivity, and statin use.
66 claims checked on air: 9 context 2 contradicted 5 overstated 47 supported 3 unverified
What they said on air - unverified
A meta-analysis review of 36 interventional trials with nearly 6,000 participants found that the combination of aerobic and resistance training provides the greatest cognitive benefit, especially in individuals age 65 or older and those with existing cognitive impairment.
"a study that was a review of 36 interventional trials where they put people on these programs, and it was close to 6,000 individuals. And their conclusion was: is it aerobics, is it resistance training? Their conclusion was it is both. It's the combination that seems to work best... And what Jiang and the other researchers in that report noticed was that the best bang for the buck, in other words the best response, was in individuals who were age 65 or older—you and me—and also those individuals who already had some cognitive impairment." (said at 0:41:30)
A specific meta-analysis by Jiang et al. encompassing exactly 36 interventional trials and nearly 6,000 participants evaluating the combined effects of aerobic and resistance exercise across age groups and baseline cognitive status could not be located in the search. This does not prove the claim or publication does not exist, but no matching published record was verified.
In 2018, approximately 11 million pounds of paraquat were used in the United States.
"My last citation that I could find was 2018; I think data is coming out this year from the US Geological Survey, but that was 11 million pounds of paraquat used." (said at 0:16:17)
No retrieved publication or dataset from the fetched records contained the specific 2018 US Geological Survey (USGS) estimate of approximately 11 million pounds of paraquat applied in the United States. While USGS National Water Quality Assessment (NAWQA) data and related environmental health literature track agricultural paraquat use in the U.S., the specific figure cited could not be confirmed within the available fetched literature. This does not prove the claim false, but leaves it unverified based on the fetched records.
Stroboscopic 40 Hz flashing light devices can cause side effects including nausea and headaches.
"Most use what's called stroboscopic light, and that's the type of light that flashes then you can see the flashing and that can cause nausea, it can cause headaches" (said at 0:28:13)
No published records detailing the specific adverse event rates (such as nausea and headache) associated with visible stroboscopic 40 Hz light stimulation devices were successfully fetched within the search limit. Consequently, the claim cannot be independently verified from the retrieved records.
Fact-checked episodes
Publications
- Could Alzheimer's disease be a maladaptation of an evolutionary survival pathway mediated by intracerebral fructose and uric acid metabolism?The American journal of clinical nutrition 2023 · CEBM Level 5
- Preventing Alzheimer's Disease.Journal of the American College of Nutrition 2016 · CEBM Level 5
- David Perlmutter, MD, FACN, ABIHM: Combating inflammation in the brain--what is good for the body is good for the brain. Interview by Karen Burnett.Advances in mind-body medicine 2013 · CEBM Level 5
- Appropriate clinical use of statins: a discussion of the evidence, scope, benefits, and risk.Alternative therapies in health and medicine 2013 · CEBM Level 5
- Differentiation between Celiac Disease, Nonceliac Gluten Sensitivity, and Their Overlapping with Crohn's Disease: A Case Series.Case reports in immunology 2013 · CEBM Level 4
- Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society 2009 · CEBM Level 2